Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.

CONCLUSION: Daprodustat 4-10 mg once-daily produced dose-dependent increase in hemoglobin relative to placebo in Japanese HD subjects. The doses evaluated in the study have moderately increased endogenous EPO without changes in circulating VEGF levels. PMID: 27978511 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27978511?dopt=Abstract

Source: American Journal of Nephrology - December 15, 2016 Category: Urology & Nephrology Authors: Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, Imai Y, Kawase N, Hara K, Lepore J, Cobitz A Tags: Am J Nephrol Source Type: research